LAUSR

Abstract Diabetes‐associated cardiovascular complications are the leading cause of death for diabetic patients. Dipeptidyl peptidase 4 (DPP‐4) inhibitor agents, known as gliptins, are a class of potent anti‐glycemic agents developed to treat diabetes. Recently, gliptins have been shown to have independent cardiovascular benefits. In this study, we revealed the protective role of saxagliptin in vascular endothelial cells. Our data show that saxagliptin suppresses oxidized low‐density lipoprotein cholesterol (ox‐LDL)‐induced expression of its receptor lectin‐like ox‐LDL receptor‐1 (LOX‐1). Saxagliptin treatment reduces ox‐LDL‐induced production of cytokines and vascular adhesion molecules including tumor necrosis factor (TNF‐&agr;), interleukin‐1&bgr; (IL‐1&bgr;), vascular cell adhesion molecule 1 (VCAM‐1), and intercellular cell adhesion molecule‐1 (ICAM‐1). The presence of saxagliptin suppressed ox‐LDL‐induced adhesion of monocytes to endothelial cells in co‐culture adhesion experiments. Moreover, saxagliptin mitigated ox‐LDL‐induced production of reactive oxygen species and suppressed elevated expression of endothelial nicotinamide adenine dinucleotide phosphate oxidase subunit (NOX‐4) induced by ox‐LDL. Mechanistically, saxagliptin exerted inhibitory effects against ox‐LDL‐induced phosphorylation of JNK kinase, expression of the activator protein 1 (AP‐1) subunits c‐Jun/c‐fos, and AP‐1 promoter activity. Saxagliptin also suppressed nuclear factor &kgr;B (NF‐&kgr;B) p65 accumulation and inhibited its promoter activity. Our data elaborate the molecular mechanism of saxagliptin‐mediated endothelial protection and indicate that saxagliptin could have vascular benefits independent on its anti‐glycemic function.